NCT00591201 - Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

June 30, 2007

Study Completion Date

September 30, 2007

Conditions

Spondylarthropathies

Interventions

DRUG

infliximab

Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.

DRUG

Placebo

Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.

Trial Locations (1)

06720

Servicio de Reumatología, Hospital General de México, Mexico City